A respiratory expert undermines GSK’s case for new asthma drug mepolizumab – FierceBiotech


Reuters India

A respiratory expert undermines GSK's case for new asthma drug mepolizumab
FierceBiotech
Investigators for GlaxoSmithKline ($GSK) detailed their promising Phase III data for the IL-5 biologic mepolizumab in asthma today, noting that the injectable halved the rate of exacerbations among a group of patients with uncontrolled cases of the
UPDATE 1-Cost a focus as GSK takes lead in new wave of biotech lung drugsReuters UK

all 4 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *